MDS experts, Dr Alan List and Dr David Sallman, explain that the goals of therapy for patients with
higher-risk myelodysplastic syndromes (
MDS) are to improve symptoms, decrease the risk of leukemia, and improve survival. The primary
treatment options for higher-risk MDS discussed are:
hypomethylating agents (azacitidine and decitabine) and
allogeneic stem cell transplant.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.